Cefpirome

Summary

Cefpirome (CHEMBL65794) is an approved small molecule (ATC J01DE02); indicated across 1 condition including bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DE02
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 514.6 Da · C22H22N6O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL65794
Name	Cefpirome
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5479539
ChEBI	CHEBI:3503
ATC	J01DE02
Molecular formula	C22H22N6O5S2
Molecular weight	514.6
InChIKey	DKOQGJHPHLTOJR-WHRDSVKCSA-N

SMILES: CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC5=C4CCC5)C(=O)[O-]

IUPAC name: (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.

Also known as: Cefir, Cefpiroma, Cefpirome, HR-810 FREE BASE, cefpirome, SID50125933, CEFPIROME

Parent form; salt/anhydrous children: CHEMBL2106076

Patent coverage: 2,485 distinct patent families (8,933 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,902 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00280514	PHASE4	COMPLETED	Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).